Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.

Baseline ctDNA-negativity was associated with longer RFS than positivity (event rate 20.9% [23/110] vs 80.0% [12/15]; HR 0.150, 95% CI 0.073-0.306). In the mRNA-4157/V940 plus pembrolizumab arm, RFS event rates were 10.4% (8/77) if negative vs 76.9% (10/13) if positive (HR 0.087). The pembrolizumab monotherapy comparison used only 2 ctDNA-positive patients.

ASCO Annual Meeting 2023